eLife 9:e51507
In the same study, Beyond the scale with Wegovy HD 1 Patients taking Wegovy HD pen 7.2 mg experienced improvements across most cardiometabolic risk factors Confirmatory secondary end points: Change from baseline to week 72 in 1 : Waist circumference: 5.6-inch reduction 2.2-inch reduction with placebo Supportive secondary end points: Change from baseline to week 72 in 1 : Lipid profile: Total cholesterol 3.4% reduction 4.0% reduction with placebo LDL 3.5% reduction 4.8% reduction with placebo HDL 9.5% increase 0.5% decrease with placebo Triglycerides 16.4% reduction 0.9% reduction with placebo Systolic blood pressure: 10.1 mm Hg reduction 4.8 mm Hg reduction with placebo Diastolic blood pressure: 4.5 mm Hg reduction 1.8 mm Hg reduction with placebo A1c: 0.3% reduction 0% change with placebo Safety end point: Change in 1 : Heart rate: 0.5 bpm increase 0.6 bpm reduction with placebo Wegovy is not indicated to treat hypertension, type 2 diabetes, or dyslipidemia

Some patients are more responsive to lower doses than others and pushing them to a dose faster or higher than is necessary just leads to side effects. Similarly, Kayley George, MS, RD, LD, a registered dietitian, and founder of the Ditch the Diet coaching program,told MNT that microdosing through Noom or any other platform is not necessarily different from what doctors prescribe with, for example, Ozempic the active ingredient, semaglutide, is still the same
Because of its connection to so many aspects of normal human health, b12 deficiency can manifest itself with many symptoms